Heme & Onc Emergencies Flashcards
What is Tumor Lysis?
-Massive tumor cell lysis w/ release of large amounts of K, phos, nucleic acid in systemic circulation.
-Seen in setting of high grade lymphomas (Burkitts) & ALL, can also happen in malignancies w/ high proliferative rates, large tumor burden, high sensitivity to chemo treatment
-Severe metabolic derangements
Clinical manifestations of TLS
-Increased uric acid>AKI
-Hyperphosphatemia>AKI & arrhythmias>secondary hypocalcemia>tetany & seizures
-Associated symptoms with metabolic derangements (N/V, diarrhea, anorexia, lethargy, hematuria, HF, arrhythmias, muscle cramps, tetany, syncope, stone formation occasionally)
Definition & Classification of TLS
-Cairo-Bishop: 2+ lab changes w/in 3 days before and 7 days after surgery
-Uric acid >/= 8mg/dL or 25% from baseline
-K >/= 6mEq/L or 25% increase from baseline
-Phos >/= 6.5 or 25% increase
-Ca </=7 or 25% decrease from baseline
-Creatinine >1.5x upper limits of normal
-Cardiac arrhythmias
-seizures
Management of Tumor Lysis Syndrome prophylaxis
-Hydration!!
-Hypouricemic agents such as allopurinol or rasburicase
-Monitor labs (high risk 4-6h, intermediate q8-12, low 24h).
-Strict I&Os
TLS Present-Management
-Admit (may require telemetry pending severity of electrolyte disturbances)
-Hydration (caution in heart failure)
-Treat electrolyte disturbances
-Rasburicase (hyperuricemia > 8 mg/dL or impaired renal function) versus allopurinol
Hyperphosphatemia in TLS management
-Phosphate binders *calcium acetate
*calcium carbonate
*Sevelamer
2-3 tabs/meals
1-2g/meals
800-1600mg/meals
-Dialysis (Severe)
-Low phos diet
Hypercalcemia of Malignancy
-most commonly caused either by primary hyperparathyroidism or hypercalcemia of malignancy
-Occurs in both solid and hematological malignancies
-Most common cancers associated with this is breast, renal, lung, squamous cell cancers, multiple myeloma
-ionized calcium levels most accurate (if drawing total Ca-correct for albumin if low).
Medical emergency if serum Ca is what?
> /= to 12.5 mg/dL or accompanied by AMS, ECG changes, dehydration, renal insufficiency, N/V.
Hypercalcemia workup
-PTH
-PTHrp>elevation in hypercalcemia of malignancy
-Rule out other causes: TSH, AM cortisol, SPEP/IFE, UPEP, free light chain assay, ACE level
Skeletal survey (multiple myeloma) or nuclear bone scan (other cancers)
What PTH level indicates hyperparathyroidism?
> 250 for men
200 women
Longstanding complications with hypercalcemia of malignancy
-kidney stones,
-dehydration,
-kidney failure,
-arrhythmias,
-mental status changes,
-osteoporosis and/or fracture
Denosumab
-FDA approved for management of hypercalcemia of malignancy that is refractory to bisphosphonates, especially if eGFR <35
-Expensive
-discontinue calcium and vitamin D supplements, calcium- containing antacids, and thiazide diuretics
-Initial dose 60 mg SQ with repeat dosing based upon response
-also approved for postmenopausal osteoporosis and prevention of skeletal related events from bone metastases
Management of Hypercalcemia
-NS
-Bisphosphonates
-Calcitonin
-Furosemide
-Corticosteroids
Neutropenic Fever
-Infections are common and major contributor and mortality in cancer patients
-Prompt dx and initiation of therapy is key
Definition of neutropenic fever
-Fever is defined as single oral temp >/= 38.3 or >/= to 38 sustained for more than 1 hour
-Neutropenia is defined as absolute neutrophil count (ANC) < 0.5 x 109 or an ANC that is expected to decrease to < 0.5 x 109 during the next 24 hours. Profound neutropenia is an ANC < 0.1 x 109
Nadir 5-10 days after last chemo dose
WBC recovery 7-10 days after nadir
Pathophysiology of neutropenic fever
-Those with acute leukemia
-Bone marrow dysfunction (MDS, acute leukemia, aplastic anemia)
-Patients with drug or radiation induced neutropenia
-Less common in patients with solid tumors
-Hematologic cancers
Chemo disrupts mucosal barrier making risk for what type sepsis greater?
-Gram negative